Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
City of Hope Medical Center
Novartis
University of California, Irvine
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Institute of Hematology & Blood Diseases Hospital, China
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
OHSU Knight Cancer Institute
National Cancer Institute (NCI)
Institute of Hematology & Blood Diseases Hospital, China
Guangdong Provincial People's Hospital
Massachusetts General Hospital
Memorial Sloan Kettering Cancer Center
Sanofi
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
Beijing 302 Hospital
Fred Hutchinson Cancer Center
PrECOG, LLC.
Institute of Hematology & Blood Diseases Hospital, China
National Cancer Institute (NCI)
Shanghai Jiao Tong University School of Medicine
Eastern Cooperative Oncology Group
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)
University of Leipzig
Memorial Sloan Kettering Cancer Center
Children's Mercy Hospital Kansas City
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Hospital Organization Nagoya Medical Center
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
Emory University
University of California, San Diego
Alliance for Clinical Trials in Oncology
University of Ulm
Massachusetts General Hospital